Angiogenesis Inhibition by an Oncolytic Herpes Virus Expressing Interleukin 12

Richard J. Wong, Mei-Ki Chan, Zhenkun Yu, Ronald A. Ghossein, Prasad S. Adusumilli, Brendon M. Stiles, Jatin P. Shah, Bhuvanesh Singh, and Yuman Fong

1Head and Neck Service, 2Hepatobiliary Service, Department of Surgery, and 3Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York

ABSTRACT

Purpose: Oncolytic herpes simplex viruses (HSV) may have significant antitumor effects resulting from the direct lysis of cancer cells. HSVs may also be used to express inserted transgenes to exploit additional therapeutic strategies. The ability of an interleukin (IL)-12-expressing HSV to treat squamous cell carcinoma (SCC) by inhibition of tumor angiogenesis is investigated in this study.

Experimental Design: A replication-competent, attenuated, oncolytic HSV carrying the murine IL-12 gene (NV1042), its non-cytokine-carrying analog (NV1023), or saline was used to treat established murine SCC flank tumors by intratumoral injection. The expression of secondary antiangiogenic mediators was measured. Angiogenesis inhibition was assessed by in vivo Matrigel plug assays, flank tumor subdermal vascularity, and in vitro endothelial cell tubule formation assay.

Results: Intratumoral injections of NV1042 (2 × 10^7 plaque-forming units) into murine SCC VII flank tumors resulted in smaller tumor volumes as compared with NV1023 or saline. IL-12 and IFN-γ expression in tumors was 440 and 2.2 pg/mg, respectively, at 24 h after NV1042 injection, but both IL-12 and IFN-γ were undetectable (<0.2 pg/mg) after NV1023 or saline injections. Expression of two antiangiogenesis mediators, monokine induced by IFN-γ and IFN-inducible protein 10, was elevated after NV1042 treatment. Matrigel plug assays of NV1042-treated SCC VII tumor cells demonstrated significantly decreased hemoglobin content and microvessel density as compared with NV1023 and PBS. Excised murine flank tumors treated with NV1042 had decreased subdermal vascularity as compared with NV1023 and PBS. Both splenocytes and IL-12 expression by NV1042 were required for in vitro inhibition of endothelial tubule formation.

Conclusions: IL-12 expression by an oncolytic herpes virus enhances therapy of SCC through antiangiogenic mechanisms. Strategies combining HSV oncolysis with angiogenesis inhibition merit further investigation for potential clinical application.

INTRODUCTION

Replication-competent, attenuated, oncolytic herpes simplex viruses (HSV) have an ability to infect and lyse a wide variety of malignant tumors. These engineered oncolytic herpes vectors have been shown to have therapeutic effects in treating animal models of brain, breast, prostate, colorectal, and head and neck cancers (1–5). Oncolytic HSVs may be effective when delivered through a variety of routes, including direct intratumoral injection, intracavity (peritoneal (6), bladder (7), and pleural (8)), lymphatic transit (9), intra-arterial perfusion (10), and i.v. administration (11).

Several Phase I clinical trials have recently demonstrated encouraging safety data for these attenuated herpes viruses (12–14). Our group has reported the construction and characterization of a series of oncolytic viruses based on the NV1020 (R7020) virus (5, 15, 16). NV1020 was originally designed as a vaccine for HSV-1 and is attenuated by deletions in one copy of the γ34.5 neurovirulence gene, UL56, and the promoter region of UL24 (5, 16). Studies in primates with R7020 demonstrated its relative safety at doses 10,000-fold higher than that of wild-type HSV-1 (17). Furthermore, an ongoing Phase I clinical trial of NV1020 for patients with metastatic colorectal carcinoma has also suggested a favorable safety profile for this oncolytic vector in patients (14).

The predominant mechanism described for the therapeutic effect of these viruses is the direct infection and lysis of malignant cells. However, immune strategies using these oncolytic herpes vectors may also be exploited by designing oncolytic viruses to express cytokine transgenes in an attempt to stimulate a host antitumoral immune response (15, 18, 19). We recently described the construction of NV1042, an attenuated, replication-competent herpes oncolytic vector that carries and expresses an inserted murine interleukin (IL)-12 gene (15). In a murine model of squamous cell carcinoma (SCC), NV1042 displayed significantly enhanced therapeutic effects in comparison with its non-IL-12-expressing analog, NV1023. This effect also conferred immunity to subsequent SCC VII challenge and was abrogated when T-lymphocyte activity was blocked (15).

IL-12 is a cytokine with stimulatory effects on helper T lymphocytes, CTLs, and natural killer cells (20). IL-12 deliv-
tered to established murine tumors may result in significant antitumor effects through the activation of CTLs and natural killer cells (21–22). IL-12 also possesses antiangiogenic effects, which result from the induction of IFN-γ from helper T lymphocytes and the subsequent stimulation of secondary mediators, including monokine induced by IFN-γ (MIG) and IFN-inducible protein 10 (IP-10; Ref. 23). Delivery of IL-12 to malignant tumors by systemic IL-12 administration, plasmid electroporation, adenoviral gene transfer, and IL-12 fusion to an antibody fragment has been shown to result in antiangiogenic effects in animal models (24–27).

The purpose of the present study is to determine whether angiogenesis inhibition may serve as a mechanism to enhance herpes oncolytic viral therapy. Angiogenesis inhibition by a herpes oncolytic vector has not been reported previously. Although IL-12 has been shown to have antiangiogenic effects, IL-12 expression by a herpes oncolytic vector may not necessarily induce effects similar to those of other methods of IL-12 delivery. The local milieu at the site of herpes oncolytic viral delivery is in significant flux, with complex interactions occurring between lysed tumor cells, released progeny viral particles, and recruited immune cells. It is not known whether IL-12-mediated angiogenesis inhibition may be induced in such an environment. The purpose of the present study was to assess the potential antiangiogenic effects of a replication-competent, oncolytic, herpes virus expressing IL-12 (NV1042) in a murine model of SCC.

MATERIALS AND METHODS

Cell Lines. The murine SCC VII cell line is a cutaneous SCC that spontaneously arose from the C3H/HeJ mouse. SCC VII is a poorly immunogenic, rapidly dividing cell line with an estimated doubling time of 18 h (28–30). SCC VII cells were grown in vitro in MEM containing 10% FCS, penicillin, and streptomycin under standard cell culture conditions. Human umbilical vein endothelial cells were grown in F12K media with 10% FCS, 1.5 g/liter sodium bicarbonate, 0.1 mg/ml heparin, 0.05 mg/ml endothelial cell growth factor, penicillin, and streptomycin. Murine splenocytes were harvested from C3H/HeJ mice and maintained in RPMI 1640 with nonessential amino acids, penicillin, streptomycin, and 2-mercaptoethanol (0.5 cc of 5.5 × 10⁻² m).

Viruses. NV1023 and NV1042 are attenuated, replication-competent, oncolytic herpes viruses whose construction has been described previously (15). NV1023 and NV1042 are derived from NV1020, a selected clone of previously described herpes strain R7020, which was originally designed as a potential vaccine (5, 15, 16). NV1020 contains deletions in UL23/4, UL56, the γ134.5 neurovirulence gene, and the internal inverted repeat (joint) region. NV1020 also contains an insertion of a HSV-2 fragment and an insertion of the endogenous copy of UL23 (thymidine kinase) into the deleted joint region. NV1023 was constructed by deleting the exogenous copy of thymidine kinase and repairing the UL23/4 locus. NV1024 was constructed by replacing the exogenous copy of thymidine kinase with murine IL-12 under the control of a hybrid α-thymidine kinase promoter and by replacing the UL23/4 locus (15). Viruses were provided by MediGene, Inc. (San Diego, CA).

Animals. Animal use was approved by the Memorial Sloan-Kettering (New York, NY) Institutional Animal Care and Use Committee. Approximately 6–8-week-old male C3H/HeJ mice (The Jackson Laboratory, Bar Harbor, ME) were used. Flank tumors were established by s.c. injection of SCC VII cells (5 × 10⁷) in 50 µl of PBS. Visible tumor nodules were reliably detected in approximately 5 days. Matrigel plugs were established by the s.c. injection of treated SCC VII cells suspended in Matrigel (BD Biosciences, Bedford, MA) into the bilateral ventral groins of mice. Injection of SCC VII cells, virus, or Matrigel into animals was performed under general anesthesia consisting of ketamine (70 µg) and xylazine (20 µg) in 100 µl of sterile water administered by i.p. injection. Animals were sacrificed by CO₂ inhalation.

Oncolytic Viral Therapy of SCC VII Flank Tumors. We sought to determine whether IL-12 expression by NV1042 may confer a therapeutic benefit for relatively large tumors, which are generally less sensitive to purely oncolytic HSV therapy. SCC VII flank tumors were established in mice. When tumors reached a size of approximately 130 mm³ in volume, tumors were measured, and animals were distributed equitably into three groups. Animals (n = 5 mice/group) were each treated with a single intratumoral injection of PBS, NV1023 (2 × 10⁷ plaque-forming units (pfu)), or NV1042 (2 × 10⁷ pfu) in 100-µl volume. Tumor dimensions were measured every 2 days, and volumes were calculated by the formula for the volume of an ellipsoid: volume = (4/3) π × (length/2) × (width/2)².

IL-12 and IFN-γ ELISA. Established s.c. SCC VII flank tumors (n = 3 tumors/group) were treated with PBS, NV1023 (2 × 10⁷ pfu), or NV1042 (2 × 10⁷ pfu) in 100-µl volume by intratumoral injection. Animals were sacrificed at days 1, 3, and 5. Tumor portions were excised, weighed, and homogenized in 1 ml of tissue lysis buffer (T-PER; Pierce Biotechnology, Rockford, IL). IL-12 and IFN-γ levels were determined by ELISA (R&D Systems, Minneapolis, MN) and quantified by spectrophotometry.

MIG and IP-10 Western Blot. Established s.c. SCC VII flank tumors (n = 3 tumors/group) were treated with PBS, NV1023 (2 × 10⁷ pfu), or NV1042 (2 × 10⁷ pfu) in 100-µl volume by intratumoral injection. Animals were sacrificed at day 1, and tumors were excised, weighed, and homogenized in tissue lysis buffer (T-PER; Pierce Biotechnology). Lysed tumor samples underwent electrophoresis on a polyacrylamide gel (Bio-Rad) and were transferred onto a polyvinylidene difluoride membrane. Primary antimouse antibodies for murine IP-10 (CRG-2; R&D Systems), MIG (R&D Systems), and actin (Santa Cruz Biotechnology) were used. An anti-IgG secondary antibody conjugated to horseradish peroxidase (Santa Cruz Biotechnology) was used to visualize IP-10 and MIG with chemiluminescence.

Matrigel Plug Hemoglobin (Hb) Assay and Microvessel Density. SCC VII cells (5 × 10⁵ cells) were infected with PBS, NV1023, or NV1042 (5 × 10⁷ viral pfu) in an Eppendorf tube for 30 min at 37°C. Treated cells were then mixed with 400 µl of cold Matrigel and injected with an insulin syringe into the ventral groins of C3H/HeJ mice. Twelve days later, animals were sacrificed, and Matrigel plugs were excised.

For the Hb assays, excised plugs (n = 6 plugs/group) were placed in 300 µl of cold PBS at 4°C overnight to liquefy the
Matrigel. Specimens were centrifuged at 14,000 rpm, and the supernatant was collected. Hb content was quantified with Drabkin’s reagent kit (Sigma-Aldrich, St. Louis, MO) and spectrophotometry.

For microvessel counting studies, excised plugs (n = 5 plugs/group) were fixed in 10% buffered formalin. Matrigel plugs were embedded in paraffin, sectioned on glass slides, and stained with H&E. Slides were reviewed by an experienced pathologist who quantified the number of microvessels per a minimum of 10 high-power fields for each excised plug.

Flank Tumor Subdermal Vascularity. Established s.c. SCC VII flank tumors of varying initial sizes were treated with a single intratumoral injection of saline, NV1023 (2 × 10⁷ pfu), or NV1042 (2 × 10⁷ pfu). Large initial tumors were selected for NV1042 injection, moderate-sized tumors were selected for NV1023 injection, and smaller tumors were selected for saline injection. One week later, animals were sacrificed, and tumors of equivalet volume were selected from each group (n = 3 tumors/group). Tumors were excised with an adjacent area of dermis and assessed for extent of tumor vascularity along the undersurface of the dermis leading to the tumor. The number of visible subdermal vessels entering the tumor was recorded.

Endothelial Cell Coculture Proliferation and Tubule Formation Assays. To assess the ability of NV1042 to inhibit endothelial cell tubule formation in vitro, a coculture experiment was performed in vitro, similar to a previously described protocol (31). Murine IL-12 has previously been demonstrated to have activity on human cells (32). Human umbilical vein endothelial cells (2 × 10⁵) were seeded in 6-well plates. SCC VII cells (3 × 10⁵) were added into Anopore membrane inserts (Nunc, Rochester, NY) with 0.02-µm pores, which were placed within the 6-well plates. These inserts allow for coculture of the two cell lines with free exchange of proteins, but no exchange of cells or viral particles. Six h later, PBS, NV1023, or NV1042 (1.5 × 10⁵ pfu) was added to the SCC VII cells. Splenocytes (2 × 10⁶) stimulated with concanavalin A (2 µg/ml) harvested from normal mice were added 24 h later into selected inserts. Cocultures were incubated for 6 days. Human umbilical vein endothelial cell proliferation from each well was calculated by lactate dehydrogenase assay (CytoTox 96 Assay; Promega, Madison, WI). Supernatant from each well (external to the insert) was collected and concentrated in a Centricon tube (YM-3; Millipore, Bedford, MA). supernatant was collected. Hb content was quantified with Drabkin’s reagent kit (Sigma-Aldrich, St. Louis, MO) and spectrophotometry.

RESULTS

Flank Tumor Volumes. Large (approximately 130-mm³) flank tumors treated with PBS, NV1023, or NV1042 demonstrated limited tumor volume reduction from treatment with the purely oncolytic NV1023 (P = nonsignificant). In contrast, tumor volumes were significantly decreased after NV1042 treatment (P < 0.05) in comparison with PBS-treated tumors (Fig. 1). At day 13 after treatment, the mean volume ± SE of PBS-treated tumors was 2780 ± 149 mm³, in comparison with 1670 ± 618 mm³ for NV1023-treated tumors and 690 ± 185 mm³ for NV1042-treated tumors. There were no observed toxicities in any animals attributable to viral therapy. There was no evidence of neurotoxicity, mucosal ulcers, poor grooming, or significant weight loss.

IL-12 and IFN-γ ELISA. Established flank tumors treated with a single intratumoral injection of PBS, NV1023, or NV1042 were excised, homogenized, and assayed for IL-12 and IFN-γ by ELISA. At day 1, the level of IL-12 was 440 pg/mg tissue, followed by a rapid decline (Fig. 2). By day 3, the level of IL-12 was 10.4 pg/mg, and by day 5, it was 2.0 pg/mg. In contrast, PBS- and NV1023-treated tumors exhibited undetectable levels of IL-12 (<0.05 pg/mg tissue) at all time points.

IFN-γ levels assessed by ELISA measured 2.2 pg/mg tissue at day 1, 1.1 pg/mg tissue at day 3, and 1.6 pg/mg tissue at day 5 in NV1042-treated tumors (Fig. 3). NV1023-treated tumors had undetectable levels of IFN-γ at days 1 and 3 (<0.2 pg/mg tissue), although at day 5, IFN-γ was slightly elevated at 0.5 pg/mg tissue. Levels of IFN-γ in PBS-treated tumors remained undetectable (<0.2 pg/mg tissue) at all time points.

MIG and IP-10 Western Blot. MIG and IP-10 were both significantly expressed in all three of the flank tumors at 24 h after intratumoral injection of NV1042, and each was highly expressed in two of the three tumors (Fig. 4). NV1023-treated tumors demonstrated lower but detectable levels of MIG and IP-10 expression. None of the saline-treated tumors demonstrated any detectable MIG or IP-10.

Matrigel Plug Hb Assay. Excised Matrigel plugs containing PBS-, NV1023-, or NV1042-treated SCC VII cells were
liquefied and assayed for Hb content. The mean Hb concentration in NV1042-treated Matrigel plugs (15 ± 2 mg Hb/g Matrigel) was significantly lower than NV1023-treated Matrigel plugs (43 ± 7 mg Hb/g Matrigel). The Hb content in the NV1023-treated Matrigel plugs was also found to be significantly lower than that in the saline-treated Matrigel plugs (93 ± 9 mg Hb/g Matrigel; $P < 0.5$, t test for both comparisons; Fig. 5).

**Matrigel Plug Endothelial Cell Density.** Histology was performed on excised Matrigel plugs, and the average number of microvessels per 10 high-power microscopic fields was quantitated. Matrigel plugs containing saline-treated SCC VII cells demonstrated significant infiltration of the Matrigel with tumor, with numerous endothelial cell-lined capillaries filled with RBCs. There were an average of 57 ± 5 microvessels/10 high-power microscopic fields in the saline-treated plugs. Matrigel plugs with NV1023-treated SCC VII cells demonstrated moderate SCC VII proliferation with an average of 67 ± 15 microvessels/10 high-power microscopic fields ($P = $ nonsignificant). In contrast, Matrigel plugs with NV1042-treated SCC VII cells displayed sparse, small tumor islands within the Matrigel, with only rare capillaries. NV1042-treated Matrigel plugs had significantly fewer microvessels than NV1023- or PBS-treated Matrigel plugs, with an average of 1.2 ± 0.7 microvessels/10 high-power microscopic fields ($P < 0.05$, t test for both comparisons; Figs. 6 and 7A).

**Flank Tumor Subdermal Vascularity.** SCC VII flank tumors of varying initial sizes were treated with intratumoral injections of saline, NV1023, or NV1042 (2 × 10^7 pfu). Seven days later, animals were sacrificed, tumors of similar size from all three groups were selected, and the tumors were excised with the adjacent dermis. Tumors from different groups demonstrated different degrees of feeding tumor vessels along the undersurface of the surrounding dermis. Saline-treated tumors displayed...
multiple large feeding blood vessels (mean, 6.7 ± 1.2). NV1023-treated tumors demonstrated moderate numbers of blood vessels (5.5 ± 1.5), whereas NV1042-treated tumors demonstrated fewer and more narrowed blood vessels (mean, 3.5 ± 0.3; Fig. 7 B).

Endothelial Cell Coculture Tubule Formation and Proliferation Assay. Endothelial cells cocultured with SCC VII cells treated with PBS, NV1023, or NV1042 showed no significant differences in endothelial cell proliferation rates as measured by lactate dehydrogenase assay (data not shown). Endothelial cells were then grown on Matrigel in coculture supernatants from these groups to observe tubule formation. Endothelial cells grown in complete media showed intact tubule formation, whereas the addition of endostatin inhibited tubule formation. Endothelial cells grown with concentrated supernatant from NV1023- or NV1042-treated SCC VII cells without added splenocytes demonstrated intact tubule formation. Similarly, endothelial cells grown in supernatant from NV1023-treated SCC VII cells with splenocytes also demonstrated intact tubule formation. In contrast, supernatant from NV1042-treated SCC VII cells with added splenocytes led to an inhibition of endothelial cell tubule formation (Fig. 8). This finding suggests that both IL-12 expression by NV1042 and factors released from interacting immune cells are necessary for inhibitory effects on endothelial cell tubule formation.

DISCUSSION

Genetically attenuated, oncolytic HSVs have a remarkable ability to infect and lyse a variety of malignant tumors and are promising cancer therapy agents that have recently reached clinical trials. Furthermore, these DNA viruses allow for relatively large genes of up to 30 kb in size to be inserted into their genome (33). The potential for designing oncolytic herpes viruses to express inserted transgenes opens many possibilities for developing treatment strategies in combination with viral oncolysis. Cytokine gene transfer is one promising strategy. With this approach, an immunostimulatory cytokine carried by the oncolytic virus is initially expressed by infected tumor cells. The herpes virus may then replicate and lyse the infected cells, releasing progeny virus to potentially infect other tumor cells. This approach therefore provides (a) cytokine production at the site of the tumor to recruit and stimulate host immune cells; (b) direct lysis of tumor cells; (c) a local environment rich in tumor debris and antigen, to which immune cells have been recruited; and (d) a release of progeny virus to potentially treat other tumor cells. An attractive advantage of this combination strategy is that
Angiogenesis Inhibition by IL-12 HSV

that expresses murine IL-12 under the control of an NV1042, a replication-competent, attenuated oncolytic HSV viruses (15, 19). Our group described the construction of strategies have recently been explored with oncolytic herpes may have significant antitumoral activity (20). IL-12 immune helper T cells, cytotoxic T cells, and natural killer cells, which

cells such as dendritic cells, monocytes, macrophages, and B lymphocytes. IL-12 is normally secreted by antigen-presenting cells such as dendritic cells, monocytes, macrophages, and B lymphocytes. IL-12 stimulates the proliferation and activity of helper T cells, cytotoxic T cells, and natural killer cells, which

may have significant antitumoral activity (20). IL-12 immune strategies have recently been explored with oncolytic herpes viruses (15, 19). Our group described the construction of NV1042, a replication-competent, attenuated oncolytic HSV that expresses murine IL-12 under the control of an e4-thymidine kinase hybrid promoter and also expresses lacZ (15). Flank tumors treated with NV1042 exhibited significantly improved therapeutic effects in comparison with those treated with the purely oncolytic NV023 virus and demonstrated enhanced immunity to subsequent SCC VII challenge. The mechanism of the IL-12-mediated benefit appeared to be related to T-lymphocyte activity and was abrogated in a T-lymphocyte-depleted animal model.

IL-12 has been shown to possess antiangiogenic activity mediated by a stimulation of T-helper lymphocytes and an induction of IFN-γ. IFN-γ then stimulates the production of MIG (by monocytes) and IP-10 (by a variety of cells including endothelial cells), which have direct antiangiogenic activity (23). The immune and antiangiogenic mechanisms of antitumoral activity by IL-12 are closely linked to each another by the stimulation of T-helper lymphocytes. Our previous finding that blockade of CD4+ and CD8+ T lymphocytes abrogates the benefit elicited from IL-12 expression is consistent with these findings because loss of T-lymphocyte activity impedes both immune and antiangiogenic effects. IFN-γ induced by IL-12 may also have antiangiogenic effects mediated by natural killer cells (34).

Although IL-12 has previously been shown to inhibit tumor angiogenesis, such an effect after oncolytic HSV delivery has not been described previously. In contrast to previously described methods of IL-12 delivery, the site of oncolytic viral application is a complex mix of infectious viral particles, infected and necrotic tumor cells, cytokines, and a variety of recruited immune cells interacting with one another. It is possible that the interaction of infectious, oncolytic HSV with the cells necessary for angiogenesis inhibition (T-lymphocytes, monocytes, and endothelial cells) might actually impede such an effect. We therefore sought to determine whether IL-12 expression by a replication-competent oncolytic virus may enhance therapy through antiangiogenic mechanisms.

NV1042 treatment of SCC VII flank tumors led to significantly smaller tumor volumes in comparison with control- and NV1023-treated tumors. Intratumoral injections of NV1042 led to a high level of IL-12 expression and the induction of secondary mediators of angiogenesis inhibition including IFN-γ, MIG, and IP-10 (Figs. 3 and 4). Although there was no detectable IL-12 elevation with NV1023 treatment, we noted a low-level elevation in levels of IFN-γ, MIG, and IP-10 after NV1023 treatment. This effect may be related to a purely oncolytic-based induction of T-helper lymphocyte activity. Previous studies have similarly suggested that HSV oncolysis of tumors in vivo may serve to induce immune cell activity, even in the absence of cytokine expression (35).

To determine whether there is a direct antiangiogenic effect in vivo, we performed Matrigel plug assays. Matrigel plugs containing NV1042-treated SCC VII cells demonstrated significantly lower Hb concentrations and microvessel density in comparison with NV1023-treated and control cells. However, differences in tumor cell proliferation were also observed, raising the question of whether differences in vascularity differences were either (a) truly primary antiangiogenic effects of NV1042 or (b) secondarily related to lower tumor volume resulting from antitumoral immune effects of IL-12. To address this question, s.c. flank tumors were treated with saline, NV1023, or NV1042 and followed for 1 week. Tumors then matched by similar volumes demonstrated fewer subdermal feeding vessels for the NV1042 group, suggesting that differences in vascularity are primarily related to IL-12 and not dependent on tumor volume.

The mechanism for IL-12-mediated angiogenesis inhibition requires the presence of T lymphocytes and monocytes to produce IFN-γ and subsequent mediators such as MIG and IP-10. We therefore performed an in vitro coculture experiment.
to (a) further demonstrate that angiogenesis inhibition by NV1042 is unrelated to differences in tumor volume and (b) demonstrate the necessity for immune cells in this effect. The ability of endothelial cells on Matrigel to migrate into tube-like patterns may be used as an assay for angiogenesis inhibition. Modeled on a previous experiment by Strasly et al. (31), we cocultured SCC VII cells infected with NV1042, NV1023, or saline with or without splenocytes. Nonviral media samples from the coculture were concentrated and then assessed for angiogenesis-inhibitory effects on an endothelial cell tubule formation assay. Both IL-12 expression by NV1042 and factors secreted from activated immune cells (splenocytes) were found to be required for inhibition of endothelial cell tube formation.

This finding is consistent with the observation of Strasly et al. (31) that IL-12 must interact with immune cells to inhibit endothelial tubule formation (31). IL-12 expression by a replication-competent oncolytic HSV was therefore able to elicit significant antiangiogenic effects.

Interestingly, there was a suggestion that the purely oncolytic NV1023 treatment might result in a very low level of antiangiogenic activity. NV1023 treatment induced a delayed, mild elevation of IFN-γ at day 5 and low but detectable levels of MIG and IP-10 expression. In comparison, there was no detectable IFN-γ, MIG, or IP-10 expression in control tumors treated with PBS. Although there was no difference in microvesel density between PBS- and NV1023-treated Matrigel plugs, Hb levels were significantly decreased in the NV1023 group in comparison with the PBS group. This difference is likely explained by our observation that the vessels in the NV1023 group tended to have a smaller caliber than those from the PBS group and were filled with fewer RBCs. In addition, tumor subdermal vascularity was reduced for NV1023-treated tumors. Viral oncolysis may, in itself, induce antitumoral T-lymphocyte activity (35). This purely oncolytic effect may lead to the low levels of IFN-γ, MIG, and IP-10 generated by NV1023. It is therefore possible that oncolytic viral therapy might induce a low level of angiogenesis inhibition that is significantly potentiated with IL-12 gene transfer.

As engineered, attenuated, oncolytic herpes viruses move closer to clinical application in the treatment of human malignancies, their great potential to exert therapeutic effects through multiple different mechanisms of activity is now a major strategic approach being exploited by many investigators. Their great potential to exert therapeutic effects through multiple different mechanisms of activity. This multifaceted approach to therapy may be beneficial in both enhancing therapeutic efficacy and potentially reducing the likelihood of tumor resistance. Understanding all of the potential mechanisms of activity by this engineered HSV may provide insights into patient selection for clinical trials. Viral oncolysis, immune stimulation, and antiangiogenesis appear to work well in concert toward achieving effective therapy. This combination strategy appears promising in preclinical studies and merits further investigation for potential future clinical application.

REFERENCES


Angiogenesis Inhibition by an Oncolytic Herpes Virus Expressing Interleukin 12

Richard J. Wong, Mei-Ki Chan, Zhenkun Yu, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/10/13/4509

Cited articles
This article cites 34 articles, 9 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/10/13/4509.full.html#ref-list-1

Citing articles
This article has been cited by 9 HighWire-hosted articles. Access the articles at:
/content/10/13/4509.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.